Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half-Year ended September 30, 2026 (Q2 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting, Financial Results, and Regulatory Disclosures under SEBI LODR

Audit Opinion:

The statutory auditors, Suryanarayana & Suresh Chartered Accountants, issued an unmodified conclusion on both standalone and consolidated financial results. The review report stated: "nothing has come to our attention that causes us to believe that the accompanying statement... contains any material misstatement."

Key Financial Highlights [Unit: ₹ Lakhs]:

Standalone Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: 3,160.74 (YoY: +30% from 2,424.30 in Q2 FY26; QoQ: +53% from 2,069.65 in Q1 FY27)
  • Total Income: 3,174.13
  • Net Profit: 391.35 (YoY: +56% from 251.43 in Q2 FY26; QoQ: +85% from 211.33 in Q1 FY27)
  • EPS: ₹4.18 (YoY: ₹2.82; QoQ: ₹2.26)

Half-Year Ended September 30, 2026:

  • Revenue from Operations: 5,230.39 (YoY: +19% from 4,384.77 in H1 FY26)
  • Total Income: 5,261.23
  • Net Profit: 602.67 (YoY: +39% from 433.51 in H1 FY26)
  • EPS: ₹6.44 (YoY: ₹4.86)

Balance Sheet (Standalone) as of September 30, 2026:

  • Cash and Cash Equivalents: 359.94
  • Other Equity: 8,517.93 (vs. 7,954.22 as of March 31, 2026)
  • Total Debt: 34,947.68 (Non-current: 15,314.64; Current: 19,633.04)

Consolidated Results:

Quarter Ended September 30, 2026:

  • Revenue from Operations: 3,160.89
  • Net Profit: 398.53 (includes share of profit from associate: 28.42)
  • EPS: ₹4.26

Half-Year Ended September 30, 2026:

  • Revenue from Operations: 5,230.54
  • Net Profit: 607.62
  • EPS: ₹6.49

Balance Sheet (Consolidated) as of September 30, 2026:

  • Cash and Cash Equivalents: 361.11
  • Other Equity: 8,333.29
  • Total Debt: 34,947.68 (same as standalone)

Segment-wise Performance:

The company operates in a single reportable business segment: "manufacturing of Active Pharmaceutical Ingredients and their intermediates" as per Ind AS 108.

Corporate Actions:

  • Dividend: The company disbursed a dividend of ₹0.40 per equity share (face value ₹1/- each) for FY26 on September 30, 2026, aggregating to ₹374.61 lakhs, as approved at the 37th AGM held on September 29, 2026.
  • No other corporate actions (buyback, split, bonus, etc.) were announced.

Resignation of Company Secretary & Compliance Officer:

  • Mr. Thirumalesh Tumma (ICSI M.No A35824) resigned as Company Secretary, Compliance Officer, and Key Managerial Personnel due to personal reasons, effective close of business hours on November 4, 2026.
  • He confirmed no other material reasons for resignation beyond personal reasons.

Appointment of Company Secretary & Compliance Officer:

  • Mr. Manohar Mollama (ICSI M.No. F11904) was appointed as Company Secretary, Compliance Officer, and Key Managerial Personnel effective November 5, 2026.
  • His profile includes over 16 years of experience in corporate governance, regulatory compliance, and legal advisory with companies including Wells Fargo, HSBC, and Cognizant.

Other Significant Information:

  • Entities included in consolidation: Subsidiaries (SMS Peptides Private Limited, SMS CoLab Private Limited), Associate (VKT Pharma Private Limited - 34.83% ownership), and Joint Venture (Chemo SMS Enterprises SL - no operations).
  • Significant subsidiary performance:
  • VKT Pharma Private Limited: Net profit of ₹81.61 lakhs (Q2) and ₹284.93 lakhs (H1)
  • SMS Peptides Private Limited: Net loss of ₹91.09 lakhs (Q2) and ₹93.79 lakhs (H1)
  • SMS CoLab Private Limited: Net loss of ₹0.36 lakhs (Q2) and ₹0.56 lakhs (H1)
  • Capital work-in-progress increased to ₹1,382.60 lakhs (standalone) from ₹1,158.24 lakhs as of March 31, 2026, indicating ongoing capex.
  • No exceptional items, extraordinary items, or changes in accounting policies were reported.